about
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesisA validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients.Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.Infections and Follicular Lymphoma: is there a Link?Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia.Epigenomic evolution in diffuse large B-cell lymphomasMinimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomibTelomeres and telomerase in normal and malignant B-cells.AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angioRandomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.N- and K-ras oncogenes in plasma cell dyscrasias.Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype.ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia.
P50
Q24654905-B26615D5-39A7-424D-AD81-2577560C3487Q31883517-91AA10D5-DA4E-40CB-82A6-519D92321599Q33408772-2D4D49C7-C3B2-4DF5-A3D7-FD02DB6FA9D5Q33415354-E7FFF2A5-10DE-42CA-A683-9757F9813D6DQ33437445-BED8C110-C0B3-42E4-9842-0E5EEF691FB0Q33642185-FEA6EF3A-F50E-435A-A194-41C611C24EDFQ34454573-4E172EF9-AAAE-4927-BFB8-E2515785166BQ34973576-DB6683A3-A969-4022-9A83-D6260B70A6FEQ35543203-FA327825-BD35-4ACE-B3DC-AD361076498EQ35759705-75213E51-4652-49DD-917A-D64258F4B658Q36141697-98BA8635-AAA7-4566-AFAE-E569DCA19072Q36234396-B47E70C6-53C7-463B-8BFF-6427A8C5C318Q36557448-20317994-B697-4D89-B8A4-65D3E5CC1E52Q36596874-BEA4FC94-D298-4BE6-8FEF-DBC379EECADBQ37552101-C1FF0065-6EBE-45B1-95E4-B3A88C9A193DQ37705182-9D372693-E0B5-4992-9CD9-BF482A5794A7Q38597474-B6B3C00F-E09F-44E1-BD26-E8F1AE98F280Q38688055-85B2F4C4-A4FC-47A0-A556-A314FA63987FQ38878814-2C18BBDB-543D-4007-8B41-80965ADA23EFQ39924019-10C2B657-8AC2-4722-9A00-13B08C773350Q40082333-BBE2EEDA-D2C7-4731-95DD-CB7A19FCE51FQ40332525-FE4ADAE8-0F97-4A83-AFE1-010C85622728Q40443044-34517804-DC48-4CD3-8191-31622458C048Q40594604-838DB35F-EFB5-4460-B416-3F3F9C188139Q41696221-AA5E2EBD-2EFE-4480-9B52-D8BDA1D8E800Q42064478-A629BAB5-E4A0-4284-A31D-4B69C5F81D37Q42120007-9F6A0DB4-097E-46B8-8375-26B8255189CBQ42336329-7DB433B9-3C10-46DE-8B75-474962D24403Q43837244-F7466530-CB98-4665-BEC6-89F74F4481B6Q44294465-79B74CEA-4739-4549-B07B-2FF9770B899AQ44564603-3C823472-9A53-4614-8717-D12C1F816EB5Q44629915-AAA282C0-F0FF-4EE4-ADFD-746EB03CEA08Q44754728-26D36853-C8CE-439F-BD64-7E091A1EF153Q45124918-B3557216-81C7-4C5C-8DE0-95A269037E4FQ45202285-DB8A65BD-F6A5-4300-BFED-1DB2478B72A5Q45270392-18038B73-8918-4FAE-8AC2-9E717FBDDAF1Q45287423-452DBC40-150C-45C3-99C8-8E16A1A64C9FQ45785426-AA90CEE1-65A8-4952-B18F-DD060CEB814EQ46563541-12940CA4-66E7-4EF8-9C90-DEEC1B3AB597Q46755084-EDF4FCBD-0DD9-4127-A219-9C65047714EB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marco Ladetto
@ast
Marco Ladetto
@en
Marco Ladetto
@es
Marco Ladetto
@nl
type
label
Marco Ladetto
@ast
Marco Ladetto
@en
Marco Ladetto
@es
Marco Ladetto
@nl
prefLabel
Marco Ladetto
@ast
Marco Ladetto
@en
Marco Ladetto
@es
Marco Ladetto
@nl
P106
P1153
6603954612
P21
P31
P496
0000-0002-8283-2681